So Monash University, the biotech facility is the world second...

So Monash University, the biotech facility is the world second best after Oxford University, responsible for the ASTRA zanica vaccine.


========================



Australian Stock Information Platform-61 Financial, June 23, medical marijuana producer IDT issued an announcement on Tuesday afternoon, June 22 that the company is working with the Victorian government, mRNA Victoria and the Monash Institute of Pharmaceutical Sciences ( MIPS) discussed the possibility that IDT may provide current Good Manufacturing Practice (cGMP) services to advance the development of Australia's first local mRNA COVID-19 vaccine candidate.

Professor Colin Pouton of MIPS said: "Monash's mRNA vaccine preclinical evaluation is progressing well, and we are now eager to cooperate with experienced pharmaceutical manufacturers to produce products for clinical evaluation. MIPS looks forward to cooperating with IDT to establish mRNA vaccine production in Australia. ability."

IDT Australia Limited CEO Dr. David Sparling said that the company is discussing and proposing its cGMP production facilities and capabilities to support the Victorian government’s commitments and initiatives to develop mRNA production capabilities. The clinically prepared vaccine candidates produced in this world-class research allow IDT to develop key technologies and infrastructure at its cGMP production base in Australia. These capabilities will be used locally for clinical and commercial applications of COVID-19 and other wide-ranging diseases.




MIPS ranks second in the world in the Faculty of Pharmacy and Pharmaceutical Sciences, second only to Oxford University, and is an Australian leader in mRNA technology. In 2020, the Monash University research team led by Professor Colin Pouton of MIPS developed Australia’s first COVID-19 mRNA candidate vaccine, and in cooperation with the Doherty Institute, received funding from the Medical Research Future Fund (MRFF) to develop the vaccine. vaccine.

In April 2021, Monash University received A$50 million in funding from the Victorian government for the development and manufacture of its mRNA vaccine.

Monash University’s world-leading experts will cooperate with the Victorian government, the University of Melbourne and research institutions including the Doherty Institute to establish and mass-produce mRNA vaccines in Victoria. Experts from the Institute of Biomedical Discovery at Monash University will also participate in the project, including mRNA experts from the fields of biotechnology, infectious diseases, immunity and cancer.

The proven scalability and relatively low-cost vaccine manufacturing potential of mRNA vaccines and nanomedicines make them a key technology platform for future vaccines and drugs. mRNA nanomedicine is also increasingly used in cancer, rare diseases, cell engineering and protein replacement therapy, so this investment will help speed up mRNA projects and develop new treatments to save lives.

IDT Australia Limited is an Australian pharmaceutical company headquartered in Victoria, Australia. The company focuses on high-safety, high-efficiency API manufacturing, finished dosage products (including β-lactam), microbiological and analytical testing, clinical packaging and pharmacy services. Its business includes research and development, clinically valuable active pharmaceutical ingredients (API), project management, chemical services, analytical chemistry, pharmaceutical services, drug development, drug development for all dosage forms, clinical packaging for early clinical trials, and regulatory affairs service.